GI Dynamics, Inc. is the developer and marketer of EndoBarrier, a device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is approved and commercially available in multiple countries outside the United States. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. The Company has developed, and continues to develop, technologies to deliver, implant and remove devices in the gastrointestinal (GI), tract. The primary purpose of these devices is to alter the GI function such that improvements in glucose control and weight loss occur. The primary product it has developed is the EndoBarrier Gastrointestinal Liner, or implant. The implant contains an anchor and a 60 centimeters impermeable sleeve that lines the duodenum and jejunum.